CHAMPIONS ONCOLOGY, INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of $100.00 thousand for the 12-month period ending 2014-04-30, per its 10-K filed 2015-07-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2015-07-29
- CHAMPIONS ONCOLOGY, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2014 was $100.00K, a 300.00% increase from fiscal 2013.
- CHAMPIONS ONCOLOGY, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2013 was $25.00K.
- CHAMPIONS ONCOLOGY, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2012 was -$57.00K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|
| 2014-04-30 | $100.00K 10-K · filed 2015-07-29 |
| 2013-04-30 | $25.00K 10-K · filed 2014-07-28 |
| 2012-04-30 | -$57.00K 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |